Waheed Nadia 4
4 · OCULAR THERAPEUTIX, INC · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Ocular Therapeutix (OCUL) CMO Nadia Waheed Sells 14,828 Shares
What Happened
Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, sold 14,828 shares of the company's common stock on June 3, 2026, for a weighted average price of $8.27, generating proceeds of approximately $122,628. This sale was not a discretionary trade but executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units vesting.
Key Details
- Transaction date: 2026-06-03 (Form 4 filed 2026-06-05). Filed timely.
- Type: Sale (sell-to-cover for tax withholding under an automatic instruction).
- Shares sold: 14,828; weighted average price: $8.27; total proceeds ≈ $122,628.
- Price range for the multiple executions: $8.2388 to $8.3000. Reporting person can provide per‑trade breakdown on request (footnote).
- Reason: Sell-to-cover election to satisfy tax withholding for RSUs vesting on June 1, 2026; instruction adopted June 1, 2024.
- Shares owned after transaction: Not disclosed in the provided filing.
Context
This was a routine, non-discretionary sell-to-cover to meet tax withholding on vested RSUs, which is common and does not by itself indicate the insider’s view on the company. The filing includes an offer to provide detailed per‑trade pricing within the reported range upon request.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-03$8.27/sh−14,828$122,628→ 300,079 total
Footnotes (2)
- [F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on June 1, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2388 to $8.3000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.